Drugs / Levonorgestrel
Levonorgestrel
Regulatory milestones approvals, filings & regulatory actions · 18 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (6) | US (FDA) | LILETTA | — | 2016-01-29 – 2023-06-29 | fda.gov ↗ |
| Label expansions (5) | US (FDA) | MIRENA | — | 2009-10-01 – 2022-08-12 | fda.gov ↗ |
| Filed | US (FDA) | LILETTA | contraception | 2018-02-22 | “Allergan and Medicines360 announced that the FDA accepted for filing the companies' sNDA for LILETTA® (Levonorgestrel-releasing Intrauterine System) 52 mg” abbvie.com ↗ |
| Label expansions (2) | US (FDA) | PLAN B ONE-STEP | — | 2013-04-30 – 2013-06-20 | fda.gov ↗ |
| Label expansions (2) | US (FDA) | PLAN B | — | 2006-08-24 – 2009-07-10 | fda.gov ↗ |
| Label expansion | US (FDA) | JADELLE | — | 2002-11-22 | fda.gov ↗ |
| Approved | US (FDA) | LO/OVRAL FE | — | 1979-07-26 | fda.gov ↗ |
Trials 178 · started per year
today
US approved 1979
1
1
1
1
4
5
10
6
7
4
9
6
7
6
4
7
8
6
10
9
10
9
7
7
4
9
10
10
197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04423068 | Dec 2020 → Apr 2022 | pregnancy disorder | Children's Mercy Hospital Kansas City | Completed | No outcome recorded |
| Phase 171 trials · 1 met primary | ||||||
| Phase 1 | NCT07808060 | Sep 2026 → Jun 2027 expected | obesity disorder | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 1 | NCT07792408 | Sep 2026 → Mar 2027 expected | autosomal dominant polycystic kidney disease | Vertex Pharmaceuticals Incorporated | Recruiting | No outcome recorded |
| Phase 1 | NCT07710729 | Jul 2026 → Apr 2027 expected | obesity disorder | Novo Nordisk A/S | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07851649 | Jul → Sep 2026 overdue | — | Corium Innovations, Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT07539090 | Jun → Oct 2026 expected | — | Deciphera Pharmaceuticals, LLC | Recruiting | No outcome recorded |
| Phase 1 | NCT07525791 | Apr 2026 → May 2027 expected | obesity disorder | Novo Nordisk A/S | Active not recruiting | No outcome recorded |
| Phase 1 | NCT07502417 | Mar → Jul 2026 overdue | — | AbbVie | Active not recruiting | No outcome recorded |
| Phase 1 | NCT07414784 | Feb → Aug 2026 | — | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT07388511 | Feb → Apr 2026 | — | Blueprint Medicines Corporation | Completed | No outcome recorded |
| Phase 1 | NCT07272889 | Dec 2025 → Feb 2026 | — | Atea Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT07190430 | Oct → Dec 2025 | atopic eczema | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT07074327 | Jul 2025 → Feb 2026 | autosomal dominant polycystic kidney disease | Vertex Pharmaceuticals Incorporated | Completed | No outcome recorded |
| Phase 1 | NCT07013643 | Jun 2025 → Jul 2027 expected | — | AstraZeneca | Recruiting | No outcome recorded |
| Phase 1 | NCT06942936 | May 2025 → Jan 2026 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT06793943 | Jan → Mar 2025 | — | Takeda | Completed | No outcome recorded |
| Phase 1 | NCT06799884 | Jan → Feb 2025 | — | Idorsia Pharmaceuticals Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06657105 | Nov 2024 → Feb 2025 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT06671405 | Sep 2024 → Feb 2025 | hyperlipidemia | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT06513104 | Jul 2024 → Sep 2025 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT06461039 | Jun 2024 → Mar 2025 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT06380205 | May → Jun 2024 | — | Incyte Corporation | Completed | No outcome recorded |
| Phase 1 | NCT05896384 | Dec 2023 → Feb 2025 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT06188026 | Dec 2023 → Dec 2024 | — | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT05613777 | Nov 2022 → Oct 2023 | — | Boehringer Ingelheim | Completed | Met primary |
| Phase 1 | NCT05505162 | Aug 2022 → Jan 2023 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT05041699 | Jun 2022 → Oct 2024 | hemorrhagic disease | International Partnership for Microbicides, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05093205 | Oct 2021 → Jul 2022 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT04972396 | Sep 2021 → May 2022 | metabolic dysfunction-associated steatohepatitis | Altimmune, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04194905 | Nov 2020 | — | Laboratorios Andromaco S.A. | Completed | No outcome recorded |
| Phase 1 | NCT04230070 | Oct 2020 | — | Laboratorios Andromaco S.A. | Completed | No outcome recorded |
| Phase 1 | NCT04267250 | Aug → Nov 2020 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT04309643 | Jun 2020 | — | Concert Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT04255277 | Jan 2020 → Sep 2021 | — | Viatris Innovation GmbH | Completed | No outcome recorded |
| Phase 1 | NCT04142762 | Oct 2019 → Jan 2020 | chronic hepatitis B virus infection | Assembly Biosciences | Completed | No outcome recorded |
| Phase 1 | NCT04074174 | Sep 2019 → Mar 2020 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT04018274 | Aug → Oct 2019 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT03557619 | Jul 2019 → Mar 2026 overdue | hematopoietic and lymphoid cell neoplasm | AbbVie | Recruiting | No outcome recorded |
| Phase 1 | NCT03984825 | Jun → Aug 2019 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 1 | NCT03954366 | Apr → Dec 2019 | neoplasm | pharmaand GmbH | Completed | No outcome recorded |
| Phase 1 | NCT03709355 | Nov 2018 → Sep 2019 | HIV infectious disease | Viriom | Completed | No outcome recorded |
| Phase 1 | NCT03675581 | Nov 2018 → Oct 2019 | systemic sclerosis | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT03662516 | Sep 2018 → Jan 2019 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT03467347 | Jul 2018 → Aug 2019 | — | International Partnership for Microbicides, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03506399 | Jun → Oct 2018 | — | Eli Lilly and Company | Withdrawn | No outcome recorded |
| Phase 1 | NCT03353857 | Nov 2017 → Jul 2018 | — | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT03478020 | Nov 2017 → Mar 2018 | — | Aquinox Pharmaceuticals (Canada) Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03324685 | Nov 2017 → Mar 2018 | — | Biogen | Completed | No outcome recorded |
| Phase 1 | NCT03301207 | Oct 2017 → Jul 2018 | B-cell chronic lymphocytic leukemia | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT03279120 | Sep 2017 → Dec 2018 | — | CONRAD | Completed | No outcome recorded |
| Phase 1 | NCT03249402 | Aug → Nov 2017 | — | Janssen-Cilag International NV | Completed | No outcome recorded |
| Phase 1 | NCT02855346 | May → Aug 2017 | — | International Partnership for Microbicides, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02846142 | Jun 2016 → Mar 2017 | — | Proteostasis Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02751385 | May 2016 → Nov 2017 | non-small cell lung carcinoma | Boehringer Ingelheim | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT02641990 | Dec 2015 → Feb 2016 | — | Intarcia Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT02545452 | Sep 2015 → Mar 2016 | endometriosis | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT02235662 | Oct 2014 → Dec 2015 | HIV infectious disease | CONRAD | Completed | No outcome recorded |
| Phase 1 | NCT02159131 | Aug → Dec 2014 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 1 | NCT01570244 | Apr → Aug 2012 | chronic hepatitis C virus infection | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT01375946 | May → Jun 2011 | — | Agile Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT01324505 | Mar 2011 → Jan 2012 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT00918476 | Jun 2010 → Feb 2011 | hepatitis C virus infection | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01137708 | Jun → Jul 2010 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT02175394 | Jul → Oct 2008 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT01714193 | Feb → Mar 2008 | — | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
| Phase 1 | NCT00508911 | Jun → Oct 2007 | social phobia | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 1 | NCT00482963 | May 2007 → Dec 2008 | HIV infectious disease | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 1 | NCT00483535 | Mar → Nov 2007 | bipolar disorder | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 1 | NCT01508858 | Nov 2006 → Apr 2007 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT00319163 | May → Nov 2006 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00254800 | Nov 2005 → Aug 2006 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02281448 | Mar → May 2005 | epilepsy | Bial - Portela C S.A. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01623466 | Jul → Sep 2012 | — | Agile Therapeutics | Completed | No outcome recorded |
| Phase 223 trials · 2 met primary · 2 missed | ||||||
| Phase 2 | NCT07010146 | Oct 2025 → Dec 2029 expected | bone remodeling disease, functional hypothalamic amenorrhea | University of Virginia | Recruiting | No outcome recorded |
| Phase 2 | NCT05695352 | Jun 2022 → Nov 2024 | — | InnovaGyn, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04676776 | Jan → Dec 2021 | — | Gynuity Health Projects | Unknown | No outcome recorded |
| Phase 2 | NCT03875378 | Aug 2020 → Aug 2028 expected | anorexia nervosa | Pouneh K. Fazeli, MD | Recruiting | No outcome recorded |
| Phase 2 | NCT05492487 | Jan 2020 → Mar 2023 | atypical endometrial hyperplasia, infertility disorder | KK Women's and Children's Hospital | Unknown | Met primary |
| Phase 2 | NCT03819114 | May 2019 → Nov 2020 | HIV infectious disease, tuberculosis | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Completed | No outcome recorded |
| Phase 2 | NCT03762382 | Dec 2018 → Aug 2019 | HIV infectious disease | CONRAD | Unknown | No outcome recorded |
| Phase 2 | NCT03589027 | Aug 2018 → Jun 2019 | HIV infectious disease | Makerere University | Unknown | No outcome recorded |
| Phase 2 | NCT03455075 | Apr 2018 → Mar 2020 | — | Premier Research | Completed | No outcome recorded |
| Phase 2 | NCT02722421 | Apr 2017 → Dec 2019 | HIV infectious disease | University of Nebraska | Completed | No outcome recorded |
| Phase 2 | NCT02203331 | Oct 2014 → Oct 2016 | endometriosis | Bayer | Completed | Missed primary |
| Phase 2 | NCT01968135 | Oct 2013 → Nov 2014 | uterine disorder | University of Colorado, Denver | Completed | Met primary |
| Phase 2 | NCT01686126 | Dec 2012 → Oct 2022 overdue | atypical endometrial hyperplasia, endometrial endometrioid adenocarcinoma | Queensland Centre for Gynaecological Cancer | Active not recruiting | No outcome recorded |
| Phase 2 | NCT00924560 | Jun 2009 → Aug 2012 | — | Duramed Research | Completed | No outcome recorded |
| Phase 2 | NCT00781456 | Jan 2009 → Aug 2011 | migraine disorder | Duramed Research | Completed | Missed primary |
| Phase 2 | NCT00445887 | Mar 2008 → Dec 2013 | ovarian carcinoma | Gynecologic Oncology Group | Completed | No outcome recorded |
| Phase 2 | NCT01250210 | Sep 2007 → Feb 2008 | anovulation | Agile Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT00394771 | Oct 2006 → Mar 2008 | — | Duramed Research | Completed | No outcome recorded |
| Phase 2 | NCT00318799 | Apr 2006 → May 2007 | — | Bayer | Completed | No outcome recorded |
| Phase 2 | NCT00196313 | May 2005 → Oct 2008 | dysmenorrhea | Duramed Research | Completed | No outcome recorded |
| Phase 2 | NCT00185380 | Apr 2005 → Dec 2008 | — | Bayer | Completed | No outcome recorded |
| Phase 2 | NCT00213096 | Mar 2003 → Feb 2004 | — | Population Council | Completed | No outcome recorded |
| Phase 2 | NCT00254189 | Dec 2002 → Oct 2004 | anovulation | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 2/34 trials · 1 met primary | ||||||
| Phase 2/3 | NCT06492889 | Jul 2024 → Jun 2025 overdue | pregnancy disorder | Gynuity Health Projects | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT05316493 | Jun 2022 → Feb 2026 overdue | atypical endometrial hyperplasia, infertility disorder | Xiaojun Chen | Recruiting | No outcome recorded |
| Phase 2/3 | NCT00310791 | Apr 2004 → Oct 2009 | anorexia nervosa | Boston Children's Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT00271583 | Sep 1999 → Sep 2001 | — | University of Pittsburgh | Completed | Met primary |
| Phase 336 trials · 2 met primary · 1 missed | ||||||
| Phase 3 | NCT04457076 | Jun 2026 → Jun 2030 expected | — | Sebela Women's Health Inc. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06904274 | Nov 2025 → Jun 2026 | endometrial hyperplasia without atypia | Bayer | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT06727734 | Jan 2025 → Sep 2027 expected | — | The University of Hong Kong | Recruiting | No outcome recorded |
| Phase 3 | NCT06019533 | Aug 2023 → Aug 2025 | — | Chemo Research | Completed | No outcome recorded |
| Phase 3 | NCT04897217 | Jun 2023 → Oct 2024 | atypical endometrial hyperplasia | Wake Forest University Health Sciences | Withdrawn | No outcome recorded |
| Phase 3 | NCT04007874 | Sep 2019 → Dec 2024 | migraine disorder | Leiden University Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT03642210 | Jan 2019 → Oct 2021 | menstrual disorder | Medicines360 | Completed | No outcome recorded |
| Phase 3 | NCT03074045 | Mar 2017 → Sep 2018 | — | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT02985541 | Dec 2016 → May 2021 | — | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT02403401 | May 2015 → Jul 2016 | — | Bayer | Completed | Missed primary |
| Phase 3 | NCT02362711 | Feb 2015 → Jan 2017 | dysmenorrhea | Nobelpharma | Completed | No outcome recorded |
| Phase 3 | NCT02158572 | Aug 2014 → Nov 2016 | — | Agile Therapeutics | Completed | No outcome recorded |
| Phase 3 | NCT01480778 | Jul 2014 → Apr 2015 | — | Azidus Brasil | Completed | No outcome recorded |
| Phase 3 | NCT03359057 | Feb → Jul 2013 | — | Galeno Desenvolvimento de Pesquisas Clínicas | Completed | No outcome recorded |
| Phase 3 | NCT02021097 | Feb 2012 → Feb 2015 | — | Regenex Pharmaceutical, China | Unknown | No outcome recorded |
| Phase 3 | NCT01434160 | Sep 2011 → Jun 2013 | — | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT01397097 | Sep 2011 → Jun 2013 | — | Bayer | Completed | Met primary |
| Phase 3 | NCT01254292 | Jan 2011 → Jan 2013 | — | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT01181479 | Aug 2010 → Dec 2011 | — | Agile Therapeutics | Completed | No outcome recorded |
| Phase 3 | NCT00922233 | Jan → Nov 2010 | — | FHI 360 | Completed | No outcome recorded |
| Phase 3 | NCT00996580 | Oct 2009 → Sep 2011 | — | Teva Women's Health | Completed | No outcome recorded |
| Phase 3 | NCT00884260 | Apr 2009 → Jun 2013 | — | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00777556 | Oct 2008 → Dec 2010 | — | Duramed Research | Completed | No outcome recorded |
| Phase 3 | NCT00528112 | Aug 2007 → Jul 2011 | — | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00360490 | Jul 2006 → Jun 2008 | menstrual disorder | Bayer | Completed | Met primary |
| Phase 3 | NCT00195559 | Sep 2005 → Dec 2007 | premenstrual dysphoric disorder | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00128934 | Aug 2005 → Dec 2007 | premenstrual tension | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | Mixed |
| Phase 3 | NCT00117260 | Jul 2005 → Jul 2007 | — | Duramed Research | Withdrawn | No outcome recorded Stop: Business |
| Phase 3 | NCT00161681 | Jul 2005 → Aug 2006 | premenstrual tension | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00229996 | Jul 2004 → ? | endometriosis, pelvis syndrome | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Completed | No outcome recorded |
| Phase 3 | NCT00220324 | Feb 2004 → Nov 2005 | — | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00196352 | May 2003 → Nov 2006 | — | Duramed Research | Completed | No outcome recorded |
| Phase 3 | NCT00245921 | Feb 2003 → Oct 2005 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00185458 | May 2000 → May 2008 | — | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00966264 | Oct 1994 → Oct 2008 | menstrual disorder | University of Helsinki | Completed | No outcome recorded |
| Phase 3 | NCT00248963 | ? → Oct 2004 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 424 trials · 1 missed | ||||||
| Phase 4 | NCT06455969 | Jul 2024 → Aug 2026 overdue | hypogonadism, musculoskeletal system disorder | Bradley Nindl | Recruiting | No outcome recorded |
| Phase 4 | NCT05444582 | Nov 2022 → Mar 2027 expected | — | University of Utah | Recruiting | No outcome recorded |
| Phase 4 | NCT04910711 | Oct 2021 → Aug 2023 | HIV infectious disease | Botswana Harvard AIDS Institute Partnership | Unknown | No outcome recorded |
| Phase 4 | NCT03353012 | Jan → May 2018 | puerperal disorder | Chulalongkorn University | Completed | No outcome recorded |
| Phase 4 | NCT02957292 | Jun 2016 → Sep 2020 | — | Sant Pau Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT02480647 | May 2016 → Aug 2017 | endometriosis | University of Campinas, Brazil | Completed | No outcome recorded |
| Phase 4 | NCT02531321 | Aug 2015 → Nov 2016 | HIV infectious disease | University of Southern California | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT02689804 | Jul → Dec 2015 | — | Columbia University | Completed | No outcome recorded |
| Phase 4 | NCT02534688 | Jun 2015 → May 2016 | endometriosis | King Chulalongkorn Memorial Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02408692 | Feb → Jul 2015 | — | Oregon Health and Science University | Completed | No outcome recorded |
| Phase 4 | NCT02121067 | Sep 2014 → Jun 2016 | — | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Phase 4 | NCT01990703 | Jan 2014 → Nov 2016 | — | University of Utah | Completed | No outcome recorded |
| Phase 4 | NCT01941134 | Apr 2013 → Dec 2017 | — | Johns Hopkins University | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01757249 | Jan → Nov 2013 | infertility disorder | University of Oxford | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01594476 | Mar 2012 → Apr 2014 | — | Oregon Health and Science University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01299116 | Dec 2011 → Jun 2016 | — | FHI 360 | Completed | No outcome recorded |
| Phase 4 | NCT02362373 | Aug 2011 → Jan 2014 | epilepsy | Columbia University | Completed | No outcome recorded |
| Phase 4 | NCT01170390 | Sep 2009 → Mar 2011 | — | Oregon Health and Science University | Completed | No outcome recorded |
| Phase 4 | NCT00997932 | Jun 2009 → Oct 2010 | — | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Phase 4 | NCT00570440 | Aug 2007 → Oct 2010 | — | FHI 360 | Completed | No outcome recorded |
| Phase 4 | NCT00475228 | Mar 2007 → Nov 2009 | — | University of Pittsburgh | Completed | Missed primary |
| Phase 4 | NCT00393198 | Oct 2006 → Oct 2012 | menstrual disorder | Bayer | Completed | No outcome recorded |
| Phase 4 | NCT00204451 | Jul 2005 → Jun 2006 | — | University of Saskatchewan | Completed | No outcome recorded |
| Phase 4 | NCT00696202 | Sep 2003 → Mar 2005 | uterine inflammatory disease | Bayer | Completed | No outcome recorded |
| Phase not applicable18 trials · 2 missed | ||||||
| — | NCT06620939 | Dec 2024 → Dec 2028 expected | endometrial polyp | Zhang Jian | Not yet recruiting | No outcome recorded |
| — | NCT06468215 | Jul 2024 → Jul 2028 expected | endometrial endometrioid adenocarcinoma | Peking University People's Hospital | Not yet recruiting | No outcome recorded |
| — | NCT04778514 | Dec 2022 → Sep 2023 | HIV infectious disease | Population Council | Completed | No outcome recorded |
| — | NCT05212389 | Dec 2021 → Aug 2024 | disease by molecular mechanism, major depressive disorder | Rigshospitalet, Denmark | Unknown | No outcome recorded |
| — | NCT05044962 | Nov 2021 → Mar 2027 expected | HIV infectious disease | University of Alabama at Birmingham | Recruiting | No outcome recorded |
| — | NCT02556411 | Jun → Dec 2021 | adenomyosis, chronic pain syndrome | University of Cagliari | Unknown | No outcome recorded |
| — | NCT06560944 | Jan 2020 → Jan 2024 | — | University of Lincoln | Completed | No outcome recorded |
| — | NCT04872244 | Nov 2019 → Jun 2021 | — | Gaziosmanpasa Research and Education Hospital | Completed | No outcome recorded |
| — | NCT03043924 | Sep 2017 → Apr 2022 | polycystic ovary syndrome | University Hospital, Lille | Completed | No outcome recorded |
| — | NCT05945407 | Aug 2016 → Dec 2023 overdue | endometrial cancer, endometrial endometrioid adenocarcinoma | Peking University People's Hospital | Recruiting | No outcome recorded |
| — | NCT01546454 | Feb → Jun 2012 | coronary artery disorder | Oregon Health and Science University | Completed | No outcome recorded |
| — | NCT01240811 | Nov 2010 → Nov 2011 | — | Sharon Achilles | Completed | Missed primary |
| — | NCT01414530 | Apr 2010 → Jun 2014 | premature menopause | Samsung Medical Center | Unknown | No outcome recorded |
| — | NCT01157754 | Jun 2009 → May 2010 | infertility disorder | IVI Madrid | Completed | No outcome recorded |
| — | NCT01499602 | May 2009 → Nov 2011 | endometrial hyperplasia without atypia | Mansoura University | Completed | No outcome recorded |
| — | NCT01111929 | Jan 2009 → May 2016 | — | Assiut University | Completed | No outcome recorded |
| — | NCT00237042 | Oct 2005 → Jun 2010 | temporomandibular joint disorder | University of Washington | Completed | Missed primary |
| — | NCT00520455 | Jan 2004 → Jun 2005 | pregnancy disorder | University of Washington | Completed | No outcome recorded |
| Comparator or background therapy72 trials | ||||||
| Phase 1 | NCT05282940 Comparator | Feb → Mar 2022 | — | Laboratorios Andromaco S.A. | Completed | No outcome recorded |
| Phase 1 | NCT02170038 Background | Jun → Dec 2014 | — | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT01328184 Comparator | Apr → Jul 2011 | — | Boehringer Ingelheim | Completed | Met primary |
| Phase 1 | NCT01291004 Comparator | Jan 2011 → Mar 2012 | — | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01286948 Comparator | Jan 2011 → Nov 2014 | — | Population Council | Completed | No outcome recorded |
| Phase 1/2 | NCT02957630 Comparator | Sep 2016 → Oct 2017 | — | Estetra | Completed | No outcome recorded |
| Phase 1/2 | NCT02451826 Comparator | May 2015 → Nov 2017 | anovulation | Population Council | Unknown | No outcome recorded |
| Phase 1/2 | NCT01166412 Comparator | Dec 2010 → Jul 2012 | — | Premier Research | Completed | No outcome recorded |
| Phase 2 | NCT06073184 Background | Sep 2026 → Feb 2029 expected | atypical endometrial hyperplasia, endometrial cancer | GynOncTrials | Recruiting | No outcome recorded |
| Phase 2 | NCT07288190 Background | May 2026 → May 2028 expected | HIV infectious disease, pregnancy disorder | HIV Prevention Trials Network | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05829460 Background | Mar 2025 → Apr 2030 | endometrial disorder | Washington University School of Medicine | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT05903131 Background | Oct 2024 → Oct 2028 expected | endometrial cancer | Washington University School of Medicine | Recruiting | No outcome recorded |
| Phase 2 | NCT06306131 Comparator | Dec 2023 → Nov 2025 | — | InnovaGyn, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03562624 Comparator | Jun 2018 → May 2019 | — | Bayer | Completed | No outcome recorded |
| Phase 2 | NCT02475265 Background | Jul 2015 → Jun 2018 | anorexia nervosa, osteoporosis | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 2 | NCT02490774 Comparator | Jun 2015 → May 2016 | — | Bayer | Terminated | No outcome recorded |
| Phase 2 | NCT01789879 Comparator | Mar → Sep 2014 | HIV infectious disease | University of Nebraska | Completed | No outcome recorded |
| Phase 2 | NCT01931657 Background | Aug 2013 → Dec 2015 | — | Karolinska Institutet | Completed | No outcome recorded |
| Phase 2 | NCT01252186 Comparator | Nov 2010 → Dec 2011 | vascular hemostatic disease | Teva Women's Health | Completed | No outcome recorded |
| Phase 2 | NCT00933179 Comparator | Jun 2009 → Sep 2010 | — | Bayer | Completed | No outcome recorded |
| Phase 2 | NCT00185224 Comparator | Mar 2005 → Mar 2006 | — | Bayer | Completed | No outcome recorded |
| Phase 2/3 | NCT03614494 Comparator | Aug 2018 → Oct 2022 | — | Dr. Hang Wun Raymond Li | Completed | No outcome recorded |
| Phase 2/3 | NCT02599077 Comparator | Nov 2015 → Nov 2017 | endometriosis | Fundación Santa Fe de Bogota | Suspended | No outcome recorded |
| Phase 3 | NCT07449299 Background | Mar 2027 → Jun 2031 expected | — | University of Utah | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07536763 Comparator | Jul 2026 → Jun 2029 expected | — | Dr. Hang Wun Raymond Li | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT02616146 Comparator | Dec 2015 → Oct 2016 | — | Organon and Co | Terminated | No outcome recorded Stop: Business |
| Phase 3 | NCT00995150 Comparator | Nov 2009 → Oct 2021 | — | Medicines360 | Terminated | No outcome recorded |
| Phase 3 | NCT00920985 Comparator | Jun 2009 → Aug 2010 | — | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00909857 Comparator | Apr 2009 → Nov 2010 | primary dysmenorrhea | Bayer | Completed | Missed primary |
| Phase 3 | NCT00764881 Comparator | Jan 2009 → Jul 2010 | — | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00778609 Comparator | Dec 2008 → Dec 2010 | headache disorder, pelvis syndrome | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT01695902 Comparator | Dec 2007 → Jan 2010 | — | Uteron Pharma S.A. | Completed | No outcome recorded |
| Phase 3 | NCT00551616 Comparator | Apr 2007 → Apr 2009 | — | HRA Pharma | Completed | Met primary |
| Phase 3 | NCT00511355 Comparator | Oct 2006 → Jan 2008 | — | Organon and Co | Completed | Mixed |
| Phase 3 | NCT00511342 Comparator | Sep 2006 → Jun 2009 | — | Organon and Co | Completed | Missed primary |
| Phase 3 | NCT00185367 Comparator | Mar 2005 → Sep 2006 | — | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00196365 Background | Jan 2005 → Jul 2007 | dysmenorrhea | Duramed Research | Completed | No outcome recorded |
| Phase 4 | NCT07544966 Comparator | Jun 2026 → Apr 2028 expected | major depressive disorder | University of North Carolina, Chapel Hill | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06162611 Comparator | Nov 2023 → Apr 2028 expected | — | Lori Gawron | Recruiting | No outcome recorded |
| Phase 4 | NCT02393482 Comparator | Jun → Dec 2021 | amenorrhea, endometriosis | University of Cagliari | Unknown | No outcome recorded |
| Phase 4 | NCT04814927 Comparator | Mar 2021 → Dec 2022 | mucositis | Eastern Virginia Medical School | Completed | No outcome recorded |
| Phase 4 | NCT03537768 Comparator | Jul 2018 → Apr 2022 | — | Kimberly Myer | Terminated | No outcome recorded |
| Phase 4 | NCT03317795 Comparator | Nov 2017 → Dec 2020 | benign neoplasm of corpus uteri, menstrual disorder | Shannon K. Laughlin-Tommaso | Completed | No outcome recorded |
| Phase 4 | NCT02863445 Comparator | Jul 2017 → Jan 2021 | obesity disorder | Oregon Health and Science University | Completed | No outcome recorded |
| Phase 4 | NCT02175030 Comparator | Aug 2016 → Feb 2020 | — | University of Utah | Completed | No outcome recorded |
| Phase 4 | NCT02735551 Comparator | Apr 2016 → Mar 2017 | — | Oregon Health and Science University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT02577601 Comparator | Sep 2015 → Jun 2017 | — | Oregon Health and Science University | Completed | No outcome recorded |
| Phase 4 | NCT02103660 Comparator | Apr 2014 → Mar 2017 | HIV infectious disease | Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 4 | NCT01963403 Comparator | Dec 2013 → Jul 2015 | uterine disorder | University of California, Davis | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01569113 Comparator | Mar → Aug 2012 | — | HRA Pharma | Completed | No outcome recorded |
| Phase 4 | NCT01501448 Comparator | Jan → May 2012 | infertility disorder | IVI Madrid | Completed | No outcome recorded |
| Phase 4 | NCT01388582 Comparator | Apr → Aug 2011 | — | University of Campinas, Brazil | Completed | No outcome recorded |
| Phase 4 | NCT01295294 Background | Mar → Dec 2011 | uterine disorder | Bayer | Completed | Missed primary |
| Phase 4 | NCT02158845 Comparator | Feb 2010 → Sep 2012 | endometriosis | University of Sao Paulo | Completed | No outcome recorded |
| Phase 4 | NCT01165307 Comparator | Aug 2009 → Sep 2015 | menstrual disorder | Abimbola Famuyide | Completed | No outcome recorded |
| Phase 4 | NCT00433004 Comparator | Feb 2007 → Oct 2010 | puerperal disorder | University of Pennsylvania | Completed | No outcome recorded |
| Phase 4 | NCT00827632 Comparator | Jul 2006 → Dec 2008 | ovarian dysfunction | Columbia University | Completed | No outcome recorded |
| Phase 4 | NCT00662454 Comparator | Jan → May 2006 | — | Oregon Health and Science University | Completed | No outcome recorded |
| Phase 4 | NCT00498784 Background | Nov 2005 → Oct 2007 | — | Bayer | Completed | No outcome recorded |
| Phase 4 | NCT00131885 Comparator | Aug 2005 → May 2008 | — | University of Utah | Completed | No outcome recorded |
| Phase 4 | NCT00206622 Comparator | Dec 2004 → Feb 2006 | — | Bayer | Completed | No outcome recorded |
| Phase 4 | NCT01044056 Comparator | Mar → Jun 2004 | — | Organon and Co | Completed | No outcome recorded |
| Phase 4 | NCT00651846 Comparator | Jun 2003 → Feb 2005 | — | Bayer | Completed | No outcome recorded |
| — | NCT07627958 Comparator | Jul 2026 → Jul 2029 expected | — | Seattle Children's Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07264933 Comparator | Feb → Aug 2025 | uterine disorder | Benha University | Completed | No outcome recorded |
| — | NCT06689150 Comparator | Aug 2023 → Aug 2024 | — | Al-Azhar University | Completed | No outcome recorded |
| — | NCT05594186 Comparator | Mar 2019 → Oct 2022 | — | Saudi German Hospital - Madinah | Completed | No outcome recorded |
| — | NCT02550067 Comparator | Dec 2015 → Oct 2018 | HIV infectious disease | FHI 360 | Completed | No outcome recorded |
| — | NCT02934789 Comparator | Sep 2014 → Apr 2018 | — | All For Women Healthcare, Illinois | Completed | No outcome recorded |
| — | NCT01613131 Comparator | Apr 2012 → Jun 2014 | menstrual disorder | University of Colorado, Denver | Completed | No outcome recorded |
| — | NCT02257671 Comparator | Feb 2012 → Aug 2015 | — | Karolinska University Hospital | Unknown | No outcome recorded |
| — | NCT00669396 Comparator | Apr 2008 → Apr 2009 | pregnancy disorder | University of Utah | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 14
| Date | Issuer | Release |
|---|---|---|
| 2026-02-12 | Teva Canada | Regulatory Important: Voluntary Nationwide Recall PrSEASONIQUE Oral Contraceptive tevacanada.com ↗
Important: Voluntary Nationwide Recall PrSEASONIQUE Oral Contraceptive |
| 2025-06-04 | Teva Canada | Regulatory Important Information - Voluntary Nationwide Recall SEASONIQUE tevacanada.com ↗
Toronto, Canada (June 4, 2025) - Teva Canada Limited, with the knowledge of Health Canada, is initiating a nationwide voluntary Type I to the Patient (Consumer) level recall of one (1) lot of prescription drug SEASONIQUE Oral Contraceptive 2x91 Extended-Cycle Tablet Dispenser |
| 2025-05-02 | Teva Canada | Regulatory Important Information - Voluntary Nationwide Recall PrSEASONIQUE® tevacanada.com ↗
Teva Canada Limited, with the knowledge of Health Canada, is initiating a nationwide voluntary Type I to the Patient (Consumer) level recall of one (1) lot of prescription drug PrSEASONIQUE® Oral Contraception Tablets 2x91 Extended-Cycle Tablet Dispenser due to the possibility of missing tablets. |
| 2023-07-10 | Medicines360 | Regulatory FDA Approves Medicines360’s Supplemental New Drug Application for LILETTA ® (levonorgestrel-releasing intrauterine system) 52 mg as Treatment of Heavy Menstrual Bleeding medicines360.org ↗
Medicines360, a global nonprofit organization with a mission to catalyze equitable access to quality medicines for women, announced today that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg for treatment of Heavy Menstrual Bleeding (HMB) for up to five years in patients who choose intrauterine contraception as their method of contraception. |
| 2022-11-14 | Medicines360 | Regulatory FDA Approves Medicines360’s LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Eight Years medicines360.org ↗
the U.S. Food and Drug Administration (FDA) has approved Medicines360’s Supplemental New Drug Application (sNDA) to extend the duration of use of Liletta® (levonorgestrel-releasing intrauterine system) 52 mg to prevent pregnancy for up to eight years. |
| 2022-10-14 | Bayer | Regulatory Mirena® approved in Europe for extended duration of use in contraception bayer.com ↗ |
| 2022-08-18 | Bayer | Regulatory Mirena® from Bayer approved in the US for extended duration of use in contraception bayer.com ↗ |
| 2019-07-09 | AbbVie | Results Allergan Continues to Demonstrate Leadership in Migraine with 29 Presentations at the 2019 American Headache Society Annual Meeting abbvie.com ↗
Absence of Clinically Significant Drug Interactions With Coadministration of Atogepant and an Ethinyl Estradiol/Levonorgestrel Oral Contraceptive in Healthy Female Subjects: A Phase 1 Pharmacokinetic Analysis. |
| 2019-05-02 | AbbVie | Results Allergan Continues to Display Leadership in Neurosciences with 29 Presentations at 2019 American Academy of Neurology Annual Meeting abbvie.com ↗
Absence of Clinically Significant Drug Interactions with Coadministration of Atogepant and an Ethinyl Estradiol/Levonorgestrel Oral Contraceptive in Healthy Female Subjects: A Phase 1 Pharmacokinetic Analysis |
| 2018-02-22 | AbbVie | Regulatory FDA Acceptance of Medicines360's Filing for supplemental New Drug Application for LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg abbvie.com ↗
Allergan plc , (NYSE: AGN) a leading global pharmaceutical company, and Medicines360, a global nonprofit women's health pharmaceutical company with a mission of expanding access to quality medicines, today announced that the U.S. Food and Drug Administration ( FDA ) has accepted for filing Medicines360's supplemental New Drug Application (sNDA). |
| 2014-07-04 | Teva Branded Pharmaceutical Products R&D, Inc. | Regulatory Teva Receives CHMP Positive Opinion for Seasonique® Extended-Regimen Contraceptive for Marketing Authorization in Several European Countries tevapharm.com ↗
The CHMP concluded that the benefits of Seasonique® outweigh its risks clearing the way for Seasonique®’s approval by local health authorities of the European Union (EU) Member States and launch in select countries throughout Europe by the end of 2014. |
| 2013-06-21 | Teva Branded Pharmaceutical Products R&D, Inc. | Regulatory FDA Approves Over-the-Counter Availability of Plan B One-Step® (levonorgestrel) for All Consumers tevapharm.com ↗
Teva Women’s Health, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that the U.S. Food and Drug Administration (FDA) has approved the emergency contraceptive Plan B One-Step® (levonorgestrel) tablet 1.5 mg for over-the-counter sale to all consumers in the United States. |
| 2013-03-29 | Teva Branded Pharmaceutical Products R&D, Inc. | Regulatory FDA Approves New Drug Application (NDA) for Teva’s Quartette™ (levonorgestrel/ethinyl estradiol and ethinyl estradiol) Tablets for the Prevention of Pregnancy tevapharm.com ↗
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved Quartette™ (levonorgestrel/ethinyl estradiol and ethinyl estradiol) tablets for the prevention of pregnancy. |
| 2009-07-13 | Teva Branded Pharmaceutical Products R&D, Inc. | Regulatory FDA Approves Plan B® One-Step, a New One-Pill Emergency Contraceptive tevapharm.com ↗
Teva Pharmaceutical Industries, Ltd. (NASDAQ: TEVA) announced today that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Plan B® One-Step emergency contraception (levonorgestrel tablet, 1.5 mg). |
All press releases naming this drug 15 releases
Evidence & citations 24 cited values
Every value below carries the sentence it was read from. 262 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | levonorgestrel | “The proposed study will use participants that currently use a specific preparation of oral contraceptive (30micrograms ethinyl estradiol and 150mg Levonorgestrel) and compare...” NCT06560944 ↗241“The volunteers received an oral single-dose of a combined contraceptive containing 30 μg ethinyloestradiol and 150 μg levonorgestrel on two occasions - once as such and once...” NCT02281448 ↗ “An Open-label, Fixed-sequence and Two-part Study to Assess the Impact of Multiple Doses of Itraconazole on the Pharmacokinetics of AZD5004 in Healthy Participants and Multiple...” NCT06942936 ↗ “The aim of this study was to investigate the bleeding pattern and cycle control of a contraceptive patch containing 0.55 mg ethinyl estradiol (EE) and 2.1 mg gestodene (GSD)...” PMID 25453585 ↗ Oct 2014 “The progestational steroid norgestrel was synthesized and tested between 1960 and 1965 through an international cooperation between Wyeth, USA and Schering, Berlin. It is a...” PMID 19936155 ↗ Nov 2009 “We evaluated the acceptability of the 90-day dapivirine levonorgestrel ring (DPV-LNG ring) used for 14 days compared to a dapivirine-only ring (DVR-200mg) in MTN-030/IPM 041 (n...” PMID 39808648 ↗ Jan 2025 “A study to assess the Pharmacokinetics (PK) of combined oral ethinyl estradiol (EE) and levonorgestrel (LNG) in healthy female participants of non-child-bearing potential, when...” NCT05505162 ↗ “A study to evaluate pharmacokinetic profile, wearability and safety of AG200-15, transdermal delivery of levonorgestrel (LNG) and ethinyl estradiol (EE), under normal...” NCT01375946 ↗ “Each women in this group will be supplied with one packet containing two 0.75 mg Levonorgestrel EC pills and advised to swallow the two tablets as soon as possible after having...” NCT01111929 ↗ “Levonorgestrel and Ethinyl Estradiol Tablets, 0.150 mg Levonorgestrel and 0.030 mg Ethinyl Estradiol taken once daily from Day 1 of menstrual period up to and including Day 28...” NCT00511342 ↗ “Participants were instructed to initiate daily oral intake of progesterone-only pills containing 0.03 mg levonorgestrel per pill (Microlut®; Bayer) at 4 weeks postpartum and at...” NCT07264933 ↗ |
| Known as | BAY86-5028 | “Initial release rate of 20µg Levonorgestrel IUS (Mirena, BAY86-5028) per day for 6 cycles.” NCT00360490 ↗8“Levonorgestrel IUS (Mirena, BAY86-5028)” NCT02985541 ↗ “Mirena (Levonorgestrel IUS, BAY86-5028)” NCT01295294 ↗ “Levonorgestrel IUD (LCS, BAY86-5028)” NCT01254292 ↗ “Levonorgestrel (Kyleena, BAY86-5028)” NCT03074045 ↗ “Levonorgestrel (Mirena, BAY86-5028)” NCT00393198 ↗ “Skyla (Levonorgestrel, BAY86-5028)” NCT01434160 ↗ “Levonorgestrel (BAY865028, Mirena)” NCT06904274 ↗ “Levonogestrel (Skyla, BAY86-5028)” NCT03562624 ↗ |
| Known as | BAY98-7196 | “Levonorgestrel (BAY98-7196)” NCT02403401 ↗ |
| Known as | Jaydess | “the levonorgestrel intrauterine system (LNG-IUS 8), which has an average levonorgestrel release rate of ∼8 μg/24 hours during the first year (total levonorgestrel content 13.5...” PMID 27016644 ↗ Mar 20162“low-dose levonorgestrel intrauterine system (LNG-IUS) total content 13.5mg (average approximate release rate 8μg/24h over the first year; LNG-IUS 8; Jaydess®)” PMID 26872720 ↗ Feb 2016 “Jaydess: Intrauterine device with a nominal in vitro release of 12 µg levonorgestrel/day” NCT02490774 ↗ |
| Known as | Kyleena | “Levonorgestrel (Kyleena, BAY86-5028)” NCT03074045 ↗ |
| Known as | LCS | “Levonorgestrel IUD (LCS, BAY86-5028)” NCT01254292 ↗ |
| Known as | LCS12 | “Low-dose Levonorgestrel Intrauterine Contraceptive System (LCS12)” NCT01434160 ↗ |
| Known as | LEVO | “Ethinyl estradiol/Levonorgestrel (EE/LEVO)” NCT07013643 ↗ |
| Known as | Levonorgestrel (LNG) emergency contraceptive (EC) | “Levonorgestrel (LNG) emergency contraceptive (EC)” NCT02689804 ↗ |
| Known as | LNG | “The aim of this study was to investigate the bleeding pattern and cycle control of a contraceptive patch containing 0.55 mg ethinyl estradiol (EE) and 2.1 mg gestodene (GSD)...” PMID 25453585 ↗ Oct 201455“A study to assess the Pharmacokinetics (PK) of combined oral ethinyl estradiol (EE) and levonorgestrel (LNG) in healthy female participants of non-child-bearing potential, when...” NCT05505162 ↗ “Participants received 12 weeks (84 consecutive days) of active combination tablets containing 150 µg levonorgestrel (LNG)/30 µg ethinyl estradiol (EE), followed by 7 days of 10...” NCT01252186 ↗ “A study to evaluate pharmacokinetic profile, wearability and safety of AG200-15, transdermal delivery of levonorgestrel (LNG) and ethinyl estradiol (EE), under normal...” NCT01375946 ↗ “OBJECTIVES: We explored levonorgestrel (LNG) concentrations, bleeding patterns and endometrial thickness in women with epilepsy (WWE) initiating an LNG-intrauterine device...” PMID 30529085 ↗ Dec 2018 “The purpose of the study is to evaluate the effect of VX-407 on the pharmacokinetics of levonorgestrel (LNG) and ethinyl estradiol (EE), norgestimate (NGM) and EE,...” NCT07074327 ↗ “This study evaluated the effect of steady-state 240 mg faldaprevir on the pharmacokinetics (PK) of an oral contraceptive containing ethinylestradiol (EE) and levonorgestrel...” PMID 25385099 ↗ Nov 2014 “women used a placebo or tenofovir (TFV) and levonorgestrel (LNG) intravaginal ring (IVR), either continuously or cyclically (three, 28-day cycles with a 3 day interruption in...” PMID 36215267 ↗ Oct 2022 “OBJECTIVE: To assess the contraceptive efficacy, safety, and tolerability of a contraceptive transdermal delivery system, (TDS; TWIRLAⓇ) containing levonorgestrel (LNG) and...” PMID 33259782 ↗ Nov 2020 “Active therapy cycle of 84 days taking combination tablets containing ascending doses of ethinyl estradiol (EE) and 150 mcg levonorgestrel (LNG), followed by a 7-day withdrawal...” NCT00394771 ↗ “Levonorgestrel and Ethinyl Estradiol (LNG-EE) Tablets, 150 mcg LNG and 30 mcg EE taken once daily from Day 1 of menstrual period up to and including Day 28 for 6 consecutive...” NCT00511355 ↗ |
| Known as | LNG-EC | “The study drugs Levonorgestrel (LNG-EC) and Ulipristal Acetate (UPA-EC) will be given in random order.” NCT02689804 ↗ |
| Known as | LNG-IUS | “the levonorgestrel intrauterine system (LNG-IUS 8), which has an average levonorgestrel release rate of ∼8 μg/24 hours during the first year (total levonorgestrel content 13.5...” PMID 27016644 ↗ Mar 20162“Levonorgesterel Intrauterine system (LNG IUS)” NCT07627958 ↗ “Levonorgestrel Intrauterine System (LNG-IUS)” NCT06620939 ↗ |
| Known as | LNG-IUS 8 | “the levonorgestrel intrauterine system (LNG-IUS 8), which has an average levonorgestrel release rate of ∼8 μg/24 hours during the first year (total levonorgestrel content 13.5...” PMID 27016644 ↗ Mar 20161“A Phase III, single-arm study of LNG-IUS 8, a low-dose levonorgestrel intrauterine contraceptive system” PMID 26872720 ↗ Feb 2016 |
| Known as | LNG-IUS; Mirena; Bayer Schering Pharma Oy, Finland | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01499602 ↗ |
| Known as | LVDS | “LVDS (Levonorgestrel Vaginal Delivery System)” NCT06019533 ↗ |
| Known as | Microlut | “levonorgestrel/ Microlut” NCT03353857 ↗ |
| Known as | Microlute | “About 100 women took Levonorgestrel (Microlute) tablet every day” NCT06689150 ↗ |
| Known as | Mirena | “The purpose of this study is to evaluate the changes in the quality of life, as well as in the sexual activity, in women inserted with MIRENA, a hormonal contraceptive...” NCT00498784 ↗17“Mirena (levonorgestrel-releasing intrauterine system), 52 mg (20 mcg/day), 5 year duration (study duration 6 months).” NCT01613131 ↗ “change the regimen to levonorgestrel intrauterine system ("Mirena") and gonadotropin-releasing hormone agonist” NCT05945407 ↗ “Initial release rate of 20µg Levonorgestrel IUS (Mirena, BAY86-5028) per day for 6 cycles.” NCT00360490 ↗ “Mirena: Intrauterine device with a nominal in vitro release of 20 µg levonorgestrel/day” NCT02490774 ↗ “Intrauterine system, marketed in the US as Mirena® (containing 52 mg of levonorgestrel)” NCT01299116 ↗ “Same day LARC placement (intervention) of Mirena, Skyla, Paragard, Implanon” NCT02735551 ↗ “Levonorgestrel-Releasing Intrauterine Contraceptive System (Mirena), 52 Mg” NCT05316493 ↗ “oral contraceptive pills, Mirena intrauterine device” NCT02934789 ↗ “Levonorgestrel IUS (Mirena, BAY86-5028)” NCT02985541 ↗ “Mirena (Levonorgestrel IUS, BAY86-5028)” NCT01295294 ↗ |
| Known as | Plan B | “Single pill of oral levonorgestrel 1.5mg X 1 dose (e.g. Plan B) same day as contraceptive implant insertion” NCT06162611 ↗2“Levonorgestrel (LNG) gel (Levogel) and oral LNG (Plan B)” NCT01286948 ↗ “Plan B (Levonorgestrel)” NCT00433004 ↗ |
| Known as | Plan B One-Step | “At the conclusion of the enrollment visit, the research coordinator will randomize each woman to receive a single-dose pill of either levonorgestrel 1.5mg (like Plan B...” NCT02689804 ↗ |
| Known as | Skyla | “the levonorgestrel intrauterine system (LNG-IUS 8), which has an average levonorgestrel release rate of ∼8 μg/24 hours during the first year (total levonorgestrel content 13.5...” PMID 27016644 ↗ Mar 20162“Skyla (Levonorgestrel, BAY86-5028)” NCT01434160 ↗ “Levonogestrel (Skyla, BAY86-5028)” NCT03562624 ↗ |
| Action | Inhibit | “oral contraceptives are used to treat symptoms of menorrhagia and dysmenorrhoea associated with endometriosis, affecting the endometrial lining by decreasing the proliferation...” NCT02599077 ↗ |
| Modality | Other / unclassified | “Mirena® IUS, Bayer-Schering, a LNG-releasing Intrauterine Delivery System (IUS)” NCT01695902 ↗ |
| Route | Oral | “Continuous oral levonorgestrel/ethinyl estradiol for treating premenstrual dysphoric disorder.” PMID 22067793 ↗ Jul 2011 |